Health
J&J’s COVID-19 vaccine 66 per cent effective in trial – The Tribune India
The vaccine is 85 per cent effective in stopping severe disease and preventing hospitalisation
January 29
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna,…
-
Noosa News21 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News14 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General14 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News6 hours agoNew playground equipment encourages children to learn through ‘risky play’